从“数”到“证-靶”——高血压中医药治疗理念与策略研究述评

方祝元; 王新东

doi:10.14148/j.issn.1672-0482.2022.0279

从“数”到“证-靶”——高血压中医药治疗理念与策略研究述评

doi: 10.14148/j.issn.1672-0482.2022.0279

方祝元^1, ,,
王新东²

1.
南京中医药大学附属医院，江苏南京 210029
2.
南京中医药大学第三临床医学院，江苏南京 210028

基金项目:

国家中医药管理局岐黄学者——国家中医药领军人才支持计划国中医药人教发〔2018〕12号

国家中医药管理局全国中医药创新骨干人才项目国家中医药管理局办人教函〔2019〕128号

详细信息

通讯作者:
方祝元，男，教授，主任中医师，博士生导师，主要从事心系疾病的研究，E-mail: fangzhuyuan@njucm.edu.cn
方祝元 1964年生，男，医学博士，主任中医师，二级教授，博士生导师。享受国务院政府特殊津贴专家，国务院学位委员会学科评议组成员，国家卫生健康委基层高血压管理办公室副主任，国家基层高血压管理专家委员会副主任委员，中华中医药学会基层高血压防治专家指导委员会主任委员，江苏省突出贡献中青年专家。南京中医药大学副校长，江苏省中医院（南京中医药大学附属医院）党委书记。国家中医药管理局岐黄学者、高血压重点研究室主任，中华中医药学会心血管专业委员会副主任委员，国家高校“十二五”规划教材《中医内科学》主编，国家“双一流”学科暨江苏高校优势学科“中医学”学科带头人，江苏省“333人才工程”第一层次青年科学家培养对象，江苏省中医药学会副会长、高血压病专业委员会主任委员，江苏省中医临床研究院院长，江苏省中西医结合高血压研究所所长、首席专家。获“全国医院优秀院长”、中华中医药学会首届“优秀管理人才”称号。法国国立行政学院高级管理研修班结业，美国哈佛大学公共卫生学院访问学者。擅长运用中医、中西医结合方法治疗高血压病、冠心病、心力衰竭、心律失常、病毒性心肌炎等心血管疾病。

中图分类号: R259.441
计量
- 文章访问数: 827
- HTML全文浏览量: 215
- PDF下载量: 57
- 被引次数: 0
出版历程
- 收稿日期: 2022-02-26
- 网络出版日期: 2022-04-13
- 发布日期: 2022-04-10

From "Numerical Value" to "Syndrome and Target": A Review of the Concept and Strategy of Hypertension Treatment in Chinese Medicine

FANG Zhu-yuan^{1
, ,},
WANG Xin-dong²

1.
The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China
2.
The Third School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, China

摘要

摘要: 围绕高血压中医药治疗从重视血压数值到重视证和靶器官终点事件的理念转变，从“血压值达标”到“越早达标越好”的策略转变，以及在继承拓展病机理论、科学阐释证候内涵、创新优化遣方用药、阐明药效靶点机制等方面的进展，对近年来高血压中医药治疗的理念、策略、方法及机制进行简要总结。针对“病初即可及靶”的认识和继承不够、创新不足、证据薄弱等问题，提出“数-证-靶”结合的高血压中医药防治与疗效评价研究策略，探讨与西药治疗“差异化、互补化、比较优势”的研究定位及以“终”(心脑肾终点)为“始”(研究出发点)的研究思路，并在明确自身定位、探索融合之术、守正升华理论、开拓组方思维、积累循证证据、创新评价方法、阐明靶点机制等方面分析展望了前沿探索方向。
- 高血压 /
- 中医药治疗 /
- 策略 /
- 述评
Abstract: A brief summary of the concepts, strategies, methods and mechanisms of Chinese medicine treatment for hypertension in recent years is presented, focusing on the conceptual shift of endpoint events from emphasizing the numerical value of blood pressure to syndromes and target organs, and the strategic shift from "meeting the blood pressure standard" to "sooner meeting the standard", as well as the progress in inheriting and expanding the pathogenesis theory, scientifically interpreting the connotation of syndrome, innovating and optimizing the use of prescriptions, and elucidating the mechanisms of pharmacological targets. In response to the problems of insufficient understanding and inheritance, short of innovation, and flimsy evidence of "reaching the target at the initial stage", we propose the research strategy of "the combination of numerical value-syndrome-target" for the prevention and treatment of hypertension with Chinese medicine and its efficacy evaluation, with the research orientation of "differentiation, complementation, and comparative advantage" of the western medicine treatment, together with the research idea of "regarding the research starting point as the ending point of heart, brain, and kidney". In addition, we analyze and prospect the frontier exploration directions in terms of clarifying our own positioning, exploring the art of integration, keeping the positive and upgrading development, expanding the formulae thinking, accumulating evidence-based facts, innovating evaluation methods, and elucidating target mechanisms.
- hypertension /
- Chinese medicine /
- strategy /
- review

HTML全文

参考文献(36)

[1]	中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56. doi: 10.3969/j.issn.1007-5410.2019.01.002 Writing Group of 2018 Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, et al. 2018 Chinese guidelines for the management of hypertension[J]. Chin J Cardiovasc Med, 2019, 24(1): 24-56. doi: 10.3969/j.issn.1007-5410.2019.01.002
[2]	UNGER T, BORGHI C, CHARCHAR F, et al. 2020 International Society of Hypertension global hypertension practice guidelines[J]. J Hypertens, 2020, 38(6): 982-1004. doi: 10.1097/HJH.0000000000002453
[3]	ZHAO XK, LI YD, FENG MX, et al. Chinese herbal medicine for the treatment of primary hypertension: A methodology overview of systematic reviews[J]. Syst Rev, 2016, 5: 180. doi: 10.1186/s13643-016-0353-y
[4]	中华中医药学会心血管病分会. 高血压中医诊疗专家共识[J]. 中国实验方剂学杂志, 2019, 25(15): 217-221. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201915033.htm Society of Cardiovascular Diseases, China Association of Chinese Medicine. Expert consensus on diagnosis and treatment of hypertension with traditional Chinese medicine[J]. Chin J Exp Tradit Med Formulae, 2019, 25(15): 217-221. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201915033.htm
[5]	国家心血管病中心国家基本公共卫生服务项目基层高血压管理办公室, 国家基层高血压管理专家委员会. 国家基层高血压防治管理指南2020版[J]. 中国循环杂志, 2021, 36(3): 209-220. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH202103001.htm The National Essential Public Health Service Program Office for Management of Hypertension in Primary Health Care, National Center for Cardiovascular Diseases. National Committee on Hypertension Management in Primary Health Care. National Clinical Practice Guidelines on the Management of Hypertension in Primary Health Care in China (2020)[J]. Chin Circ J, 2021, 36(3): 209-220. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH202103001.htm
[6]	李婕, 马思齐, 许骏尧, 等. 潜阳育阴颗粒对自发性高血压大鼠肾脏足细胞损伤的影响及其机制研究[J]. 南京中医药大学学报, 2022, 38(1): 69-76. doi: 10.14148/j.issn.1672-0482.2022.0069 LI J, MA SQ, XU JY, et al. Mechanism of Qianyang Yuyin Granule on renal podocytes injury in spontaneously hypertensive rats[J]. J Nanjing Univ Tradit Chin Med, 2022, 38(1): 69-76. doi: 10.14148/j.issn.1672-0482.2022.0069
[7]	方祝元. 中医药治疗高血压病临床述评[J]. 江苏中医药, 2019, 51(8): 1-6. doi: 10.3969/j.issn.1672-397X.2019.08.001 FANG ZY. A review of TCM treatment to hypertension[J]. Jiangsu J Tradit Chin Med, 2019, 51(8): 1-6. doi: 10.3969/j.issn.1672-397X.2019.08.001
[8]	Hypertention control report of a WHO expert committee. World Health Organ Tech Rep Ser. 1996, 862: 1-83.
[9]	GILES TD, MATERSON BJ, COHN JN, et al. Definition and classification of hypertension: An update[J]. J Clin Hypertens, 2009, 11(11): 611-614. doi: 10.1111/j.1751-7176.2009.00179.x
[10]	LENZ TL, MONAGHAN MS. Lifestyle modifications for patients with hypertension[J]. J Am Pharm Assoc, 2008, 48(4): e92-e102. doi: 10.1331/JAPhA.2008.07046
[11]	郭蕾, 乔之龙. 证候概念的状态内涵诠释[J]. 中华中医药杂志, 2015, 30(4): 1086-1088. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201504033.htm GUO L, QIAO ZL. Interpretion the connotation of the syndrome from the concept of "state"[J]. China J Tradit Chin Med Pharm, 2015, 30(4): 1086-1088. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201504033.htm
[12]	何秉贤. 高血压防治的现代理念[J]. 中国心血管杂志, 2012, 17(4): 317-318. doi: 10.3969/j.issn.1007-5410.2012.04.023 HE BX. Contemporary concept of the diagnosis and treatment of hypertension[J]. Chin J Cardiovasc Med, 2012, 17(4): 317-318. doi: 10.3969/j.issn.1007-5410.2012.04.023
[13]	ZHANG DY, CHENG YB, GUO QH, et al. Treatment of masked hypertension with a Chinese herbal formula[J]. Circulation, 2020, 142(19): 1821-1830. doi: 10.1161/CIRCULATIONAHA.120.046685
[14]	XIONG XJ, YANG XC, LIU W, et al. Banxia baizhu Tianma Decoction for essential hypertension: A systematic review of randomized controlled trials[J]. Evid Based Complementary Altern Med, 2012: 271462.
[15]	祁怡馨, 谢雁鸣, 黎元元. 基于文献分析的高血压中医证候及证候要素的研究[J]. 北京中医药大学学报, 2014, 37(11): 732-735. doi: 10.3969/j.issn.1006-2157.2014.11.003 QI YX, XIE YM, LI YY. Characteristics of Chinese medicine syndromes and syndrome elements on hypertension based on literature[J]. J Beijing Univ Tradit Chin Med, 2014, 37(11): 732-735. doi: 10.3969/j.issn.1006-2157.2014.11.003
[16]	侯雅竹, 姚红旗, 王贤良, 等. 基于2943例高血压病患者的中医证候特征分析[J]. 中华中医药杂志, 2020, 35(9): 4590-4593. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202009088.htm HOU YZ, YAO HQ, WANG XL, et al. Traditional Chinese medicine syndrome analysis on 2 943 hypertension patients[J]. China J Tradit Chin Med Pharm, 2020, 35(9): 4590-4593. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202009088.htm
[17]	张蒙, 沈建平, 董其美, 等. 从肝风心火相煽辨治阵发性心房颤动[J]. 南京中医药大学学报, 2021, 37(6): 908-911. doi: 10.14148/j.issn.1672-0482.2021.0908 ZHANG M, SHEN JP, DONG QM, et al. Identification and treatment of paroxysmal atrial fibrillation from mutual Fanning of liver wind and heart fire[J]. J Nanjing Univ Tradit Chin Med, 2021, 37(6): 908-911. doi: 10.14148/j.issn.1672-0482.2021.0908
[18]	杨坤杰, 黄敏, 李霞, 等. 高血压中医证候规范化与客观化研究进展[J]. 中华中医药学刊, 2017, 35(1): 239-242. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS201701069.htm YANG KJ, HUANG M, LI X, et al. Overview of standardization and objective syndrome differentiation of hypertension in traditional Chinese medicine[J]. Chin Arch Tradit Chin Med, 2017, 35(1): 239-242. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS201701069.htm
[19]	国家中医药管理局. 中医病证诊断疗效标准: ZY/T001.1~001.9-94[S]. 南京: 南京大学出版社, 1994: 36-37. National Administration of Traditional Chinese Medicine. Criteria of Diagnosis and Therapeutic Effect of Diseases and syndromes in Traditional Chinese Medicine: ZY/T001.1~001.9-94[S]. Nanjing: Nanjing university press: 1994: 36-37.
[20]	郑筱萸. 中药新药临床研究指导原则: 试行[M]. 北京: 中国医药科技出版社, 2002: 73-76. ZHENG XY. Guiding Principles of Clinical Research on Noval Chinese Medicine: Trial Implementation[M]. Beijing: China medical science press, 2002: 73-76.
[21]	中华中医药学会. 肿瘤中医诊疗指南[M]. 北京: 中国中医药出版社, 2008: 63-66. Society of Cardiovascular Diseases. Guideline for diagnosis and treatment of tumor in TCM[M]. Beijing: China traditional Chinese medicine press, 2008: 63-66.
[22]	韩学杰. 高血压病中医诊疗方案(初稿)[J]. 中华中医药杂志, 2008, 23(7): 611-613. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY200807018.htm HAN XJ. Chinese medical diagnosis and treatment project of hypertension(First Draft)[J]. China J Tradit Chin Med Pharm, 2008, 23(7): 611-613. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY200807018.htm
[23]	中国中医科学院. 中医循证临床实践指南: 中医内科[M]. 北京: 中国中医药出版社, 2011: 229-240. China Academy of Chinese Medical Sciences. Evidence-based Guidelines of Clinical Practice in Chinese Medicine: Internal Medicine[M]. Beijing: China traditional Chinese medicine press, 2011: 229-240.
[24]	XIONG XJ, YANG XC, LIU W, et al. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine[J]. Evid Based Complementary Altern Med, 2013, 2013: 275279.
[25]	毛凯凤, 尹鑫, 左天, 等. 史载祥教授升陷祛瘀汤加减治疗高血压病气陷血瘀证经验[J]. 中国中西医结合杂志, 2018, 38(5): 628-629. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201805032.htm MAO KF, YIN X, ZUO T, et al. Professor Shi Zaixiang's experience in treating Qi stagnation and Blood stasis syndrome of hypertension with modified Sheng Xian Qu Yu Decoction[J]. Chin J Integr Tradit West Med, 2018, 38(5): 628-629. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201805032.htm
[26]	LIU W, WANG LY, YU JH, et al. Gastrodin reduces blood pressure by intervening with RAAS and PPAR in SHRs[J]. Evid Based Complementary Altern Med, 2015, 2015: 828427.
[27]	CHEN Z, WANG LQ, YANG GY, et al. Chinese herbal medicine combined with conventional therapy for blood pressure variability in hypertension patients: A systematic review of randomized controlled trials[J]. Evid Based Complementary Altern Med, 2015, 2015: 582751.
[28]	WANG YC, MA DF, JIANG P, et al. Guizhi Decoction inhibits cholinergic transdifferentiation by regulating imbalance of NGF and LIF in salt-sensitive hypertensive heart failure rats[J]. Chin J Integr Med, 2020, 26(3): 188-196. doi: 10.1007/s11655-019-2706-6
[29]	刘玥, 张京春, 史大卓, 等. 波动性高血压与血小板活化及其中西医结合干预策略[J]. 中国中西医结合杂志, 2013, 33(7): 869-872. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201307003.htm LIU Y, ZHANG JC, SHI DZ, et al. Fluctuant hypertension and platelet activation: Current situations and control strategies with integrative medicine[J]. Chin J Integr Tradit West Med, 2013, 33(7): 869-872. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201307003.htm
[30]	JIANG YH, ZHANG P, TAO YN, et al. Banxia baizhu Tianma Decoction attenuates obesity-related hypertension[J]. J Ethnopharmacol, 2021, 266: 113453. doi: 10.1016/j.jep.2020.113453
[31]	HE AX, QIAN LJ, YAN SH, et al. Speckle tracking echocardiography verified the efficacy of Qianyangyuyin granules in alleviating left ventricular remodeling in a hypertensive rat model[J]. Evid Based Complementary Altern Med, 2021, 2021: 5862361.
[32]	QIAN LC, REN S, XU ZC, et al. Qian Yang yu Yin Granule improves renal injury of hypertension by regulating metabolic reprogramming mediated by HIF-1α/PKM2 positive feedback loop[J]. Front Pharmacol, 2021, 12: 667433. doi: 10.3389/fphar.2021.667433
[33]	张婵娟, 石雅宁, 廖端芳, 等. 高血压病血管重塑的分子机制及中医药干预[J]. 生理学报, 2019, 71(2): 235-247. https://www.cnki.com.cn/Article/CJFDTOTAL-SLXU201902006.htm ZHANG CJ, SHI YN, LIAO DF, et al. Molecular mechanism of vascular remodeling in hypertension and Chinese medicine intervention[J]. Acta Physiol Sin, 2019, 71(2): 235-247. https://www.cnki.com.cn/Article/CJFDTOTAL-SLXU201902006.htm
[34]	DENG LH, LIU W, XU Q, et al. Tianma Gouteng Decoction regulates oxidative stress and inflammation in AngⅡ-induced hypertensive mice via transcription factor EB to exert anti-hypertension effect[J]. Biomed Pharmacother, 2022, 145: 112383. doi: 10.1016/j.biopha.2021.112383
[35]	张蒙, 龚觉晓, 毛晨晗, 等. 基于机械敏感性阳离子通道Piezo1的黄芪丹参药物血清对低流体切应力诱导的人内皮细胞功能紊乱的影响[J]. 中国中医药信息杂志, 2022, 29(2): 68-73. ZHANG M, GONG JX, MAO CH, et al. Effects of Huangqi Danshen medicated serum on endothelial dysfunction induced by low fluid shear stress based on mechanosensitive channel Piezo1[J]. Chin J Inf Tradit Chin Med, 2022, 29(2): 68-73.
[36]	YANG T, SANTISTEBAN MM, RODRIGUEZ V, et al. Gut dysbiosis is linked to hypertension[J]. Hypertension, 2015, 65(6): 1331-1340. doi: 10.1161/HYPERTENSIONAHA.115.05315